Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
124 participants
INTERVENTIONAL
2020-01-01
2021-02-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nitroglycerin Versus Labetalol in Acute Severe Pre-eclampsia
NCT05310929
The Outcomes of Hypertension in Obese Versus Non-obese Pregnant Women
NCT05673135
Progesterone in Expectantly Managed Early-onset Preeclampsia
NCT04077853
Ambulatory Blood Pressure Monitoring in Post-Partum Pre-Eclamptic Patients
NCT02943122
Normotensive and Hypertensive Placental Abruptions
NCT04449601
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Carbetocin
Patient received 100 mcg of carbetocin intravenous over one minute immediately after delivery of the baby.
Carbetocin
100 mcg of Carbetocin intravenous injection
Oxytocin plus misoprostol
Patient received 10 units of oxytocin IV drip and 400 mcg of misoprostol rectally after anesthesia.
Oxytocin
10 IU oxytocin IV drip
Misoprostol
400 mcg rectal
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Carbetocin
100 mcg of Carbetocin intravenous injection
Oxytocin
10 IU oxytocin IV drip
Misoprostol
400 mcg rectal
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Singleton pregnancy.
* Termination of pregnancy by Cesarean section after 28 weeks of gestation.
Exclusion Criteria
* Known placenta Previa or acreata.
* Multiple pregnancies.
* Obesity (BMI \>35).
* Anemia (\<9 g/dl).
* Retained placental tissues.
* Big baby (\> 4 kg).
* Presence of coagulopathy.
* Polyhydramnios.
* Presence of Uterine fibroids.
* Medical diseases as; cardiac, liver, renal or endocrine diseases.
* General anesthesia.
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Mohamed Abbas
Principal investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assiut Faculty of Medicine
Asyut, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CARBOXMISO
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.